X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DR. REDDYS LAB - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DR. REDDYS LAB ASTRAZENECA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 140.4 42.7 329.0% View Chart
P/BV x 21.3 3.3 652.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ASTRAZENECA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
DR. REDDYS LAB
Mar-17
ASTRAZENECA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,2853,397 37.8%   
Low Rs6342,560 24.8%   
Sales per share (Unadj.) Rs189.6856.5 22.1%  
Earnings per share (Unadj.) Rs-0.278.0 -0.3%  
Cash flow per share (Unadj.) Rs3.8139.9 2.7%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs68.6739.8 9.3%  
Shares outstanding (eoy) m25.00165.74 15.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.13.5 145.5%   
Avg P/E ratio x-4,712.738.2 -12,335.6%  
P/CF ratio (eoy) x249.621.3 1,172.4%  
Price / Book Value ratio x14.04.0 347.2%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m23,988493,632 4.9%   
No. of employees `0001.622.7 6.9%   
Total wages/salary Rs m1,60531,068 5.2%   
Avg. sales/employee Rs Th3,040.26,259.0 48.6%   
Avg. wages/employee Rs Th1,029.21,369.8 75.1%   
Avg. net profit/employee Rs Th-3.3569.7 -0.6%   
INCOME DATA
Net Sales Rs m4,740141,961 3.3%  
Other income Rs m921,715 5.4%   
Total revenues Rs m4,832143,676 3.4%   
Gross profit Rs m-13024,722 -0.5%  
Depreciation Rs m10110,266 1.0%   
Interest Rs m0634 0.0%   
Profit before tax Rs m-13915,537 -0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m52,965 0.2%   
Profit after tax Rs m-512,921 -0.0%  
Gross profit margin %-2.717.4 -15.7%  
Effective tax rate %-3.719.1 -19.2%   
Net profit margin %-0.19.1 -1.2%  
BALANCE SHEET DATA
Current assets Rs m2,72696,837 2.8%   
Current liabilities Rs m2,43584,199 2.9%   
Net working cap to sales %6.18.9 69.1%  
Current ratio x1.11.2 97.4%  
Inventory Days Days7473 100.5%  
Debtors Days Days4198 41.7%  
Net fixed assets Rs m1,035102,552 1.0%   
Share capital Rs m50829 6.0%   
"Free" reserves Rs m942121,792 0.8%   
Net worth Rs m1,716122,621 1.4%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m4,156218,165 1.9%  
Interest coverage xNM25.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.7 175.3%   
Return on assets %-0.16.2 -2.0%  
Return on equity %-0.310.5 -2.8%  
Return on capital %012.9 0.0%  
Exports to sales %5.754.6 10.4%   
Imports to sales %6.59.4 69.1%   
Exports (fob) Rs m27077,520 0.3%   
Imports (cif) Rs m30613,274 2.3%   
Fx inflow Rs m37581,670 0.5%   
Fx outflow Rs m47026,355 1.8%   
Net fx Rs m-9655,315 -0.2%   
CASH FLOW
From Operations Rs m-821,444 -0.0%  
From Investments Rs m-146-18,404 0.8%  
From Financial Activity Rs m862-3,692 -23.4%  
Net Cashflow Rs m709-1,144 -61.9%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.4 5.6%  
FIIs % 15.7 35.3 44.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 9.1 15.3 59.5%  
Shareholders   12,856 75,885 16.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT LTD.  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 19, 2018 10:29 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS